Navigation Links
Dermata Therapeutics, LLC Closes a $5 Million Series 1a Financing and Secures a $5 Million Credit Facility with Silicon Valley Bank
Date:2/16/2017

SAN DIEGO, Feb. 16, 2017 /PRNewswire/ -- Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, today announced it has completed a $5 million Series 1a financing and entered into a $5 million credit facility with Silicon Valley Bank (SVB).  Dermata intends to use the capital for general corporate purposes to further Dermata's mission of making major advancements in the treatment of serious diseases treated by dermatologists.  

"We believe this funding strategy will provide us with the necessary capital to complete our two ongoing Phase 2 clinical studies with our lead candidate DMT210 in atopic dermatitis and rosacea. Moreover, it aligns us with a premier partner in SVB, helping us manage our cost of capital moving forward and providing the opportunity for significant value creation for our unit holders," states Gerald Proehl, President and CEO of Dermata. 

Dermata received $2.5 million at closing and, under the terms of the agreement, will receive an additional $2.5 million later this year, subject to achievement of certain specified milestones.

About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has an experienced team who are currently focused on progressing four programs for the treatment of acne rosacea, atopic dermatitis, acne vulgaris and ocular rosacea.  To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.


CONTACT:

Dermata ContactSean ProehlInvestor Relations858.223.0882sproehl@dermatarx.com


 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermata-therapeutics-llc-closes-a-5-million-series-1a-financing-and-secures-a-5-million-credit-facility-with-silicon-valley-bank-300408534.html


'/>"/>
SOURCE Dermata Therapeutics, LLC
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study
2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
3. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
4. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
5. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
6. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
7. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
8. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
9. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
10. Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma
11. Immunomic Therapeutics, Inc. Makes Significant Headway in Regulatory Interactions in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Looking for ... and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking experiences to ... cuisine, and guests leave inspired with new cooking tips and techniques, thanks to ...
(Date:4/26/2017)... ... 2017 , ... NextSteps 2017, NetDimensions’ annual global user conference, ... May on the following dates: , ?    London, UK from May 10-11, ?    New Orleans, ... Performance Institute will be the opening keynote speaker at the NextSteps EMEA ...
(Date:4/25/2017)... ... April 25, 2017 , ... L3 Clinical Trials, the Clinical ... is now a certified iMedNet eClinical and Electronic Data Capture software designer for ... research team to build, customize and manage clinical trial data capture and databases ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... denaturation in a cellular milieu; however, the broad application of this cellular target ... platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):